Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

24,446 total articles

Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026

Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026

Rhythm Pharmaceuticals announced encouraging interim six-month data from their Phase 2 trial of setmelanotide in patients with Prader-Willi Syndrome (PWS), demonstrating clinically meaningful reductions in BMI, fat mass, hyperphagia scores, and anxiety measures. These results strengthen the case for advancing setmelanotide, an MC4R agonist, into Ph…

Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema

Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema

Intellia Therapeutics reported additional positive results from its global Phase 3 HAELO trial of lonvoguran ziclumeran (lonvo-z), an in vivo CRISPR gene-editing therapy for hereditary angioedema (HAE). The treatment demonstrated an 87% reduction in monthly HAE attacks versus placebo and a favorable safety profile. The data were presented at EAACI …

Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Arcadia Biosciences (Nasdaq: RKDA) successfully closed a $4 million private placement by issuing common stock and preferred investment options at $1.03 per share, with gross proceeds intended for working capital and general corporate purposes. The offering was conducted under Section 4(a)(2) of the Securities Act and accompanied by registration rig…

Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1

Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1

Belite Bio, a clinical-stage US biopharmaceutical company, has completed the rolling submission of its New Drug Application to the FDA for tinlarebant, an investigational oral therapy targeting Stargardt disease type 1 (STGD1), a rare inherited retinal disorder with no approved treatments. The submission leverages multiple expedited regulatory desi…

ROMA Green Finance Establishes Dedicated Artificial Intelligence and High-Performance Computing Infrastructure Investment Vertical

ROMA Green Finance Establishes Dedicated Artificial Intelligence and High-Performance Computing Infrastructure Investment Vertical

ROMA Green Finance has announced the creation of a dedicated investment vertical focused on Artificial Intelligence and High-Performance Computing infrastructure, emphasizing energy-efficient, low-carbon digital assets paired with behind-the-meter power generation. This move extends their sustainable finance and ESG advisory mandate into digital in…

Heartland Express, Inc. Declares Regular Quarterly Dividend

Heartland Express, Inc. Declares Regular Quarterly Dividend

Heartland Express, Inc. announced the declaration of a regular quarterly cash dividend of $0.02 per share payable on July 6, 2026, marking the company's 92nd consecutive quarterly dividend payment. The total dividend payout is estimated at $1.6 million based on approximately 78 million shares outstanding, continuing a dividend program that began in…

Traws Pharma Provides Regulatory Update on Influenza Program

Traws Pharma Provides Regulatory Update on Influenza Program

Traws Pharma announced the deferment of its planned Phase 2a human influenza challenge study for its lead antiviral candidate, tivoxavir marboxil (TXM), due to a negative review by the UK's MHRA. Despite the setback, the company remains committed to advancing TXM and other back-up influenza antiviral compounds with improved profiles, highlighting t…

Lotus Tech Announces Operational and Earnings Reporting Updates

Lotus Tech Announces Operational and Earnings Reporting Updates

Lotus Technology Inc. announced progress on its strategic acquisition of Lotus UK aimed for 2026 closure, as part of its Focus 2030 strategy to unify brand and enhance operational efficiency. The company is temporarily suspending earnings releases for Q1 and Q3 of 2026 to prioritize acquisition compliance and integration, while continuing to report…

The Children’s Place Reports First Quarter 2026 Results

The Children’s Place Reports First Quarter 2026 Results

The Children's Place reported a Q1 2026 net sales decline of 11.1% to $215.2 million, with an operating loss of $42.2 million and net loss of $53.2 million. The company is implementing strategic initiatives focusing on customer experience, brand strength, financial targets, and leadership amid challenging retail conditions and higher tariff costs. …

Black Hills Corp. Requests Rate Review in Colorado

Black Hills Corp. Requests Rate Review in Colorado

Black Hills Corp.'s Colorado electric utility has submitted a rate review application to the Colorado Public Utilities Commission seeking $26.7 million in additional annual revenue. This is to recover approximately $184 million invested since the last rate review, particularly aimed at improving reliability and strengthening the electric grid. The …

Coffee Holding Company Reports Second Quarter Results.

Coffee Holding Company Reports Second Quarter Results.

Coffee Holding Co., Inc. reported second quarter fiscal results ending April 30, 2026, showing a 5.1% decline in net sales primarily due to a rapid 25% decline in green coffee prices. The company responded by lowering prices and increasing promotions for wholesale customers, which pressured sales volumes and profit margins. Gross profit decreased s…

Cartesian Therapeutics Announces New Employment Inducement Grant

Cartesian Therapeutics Announces New Employment Inducement Grant

Cartesian Therapeutics announced a new employment inducement award granting 6,100 stock options to a new employee at an exercise price matching the recent closing price. The options vest over four years with a ten-year term, approved by the board under Nasdaq inducement rules. The company specializes in late-stage clinical cell therapies targeting …

XOMA Royalty Corporation Declares Quarterly Preferred Stock Dividend and Announces Redemption of Its Perpetual Preferred Stock and CVR Dividend Record Date

XOMA Royalty Corporation Declares Quarterly Preferred Stock Dividend and Announces Redemption of Its Perpetual Preferred Stock and CVR Dividend Record Date

XOMA Royalty Corporation announced quarterly cash dividends for its Series A and Series B cumulative perpetual preferred stock, with payments scheduled for mid-July 2026. Furthermore, the company will redeem all outstanding preferred shares at $25 per share on July 14, 2026, ceasing dividend accrual thereafter. This redemption is in connection with…

Avista pauses processing of energy service request from 500 MW data center developer while seeking broader policy and community alignment

Avista pauses processing of energy service request from 500 MW data center developer while seeking broader policy and community alignment

Avista Corp., a US energy company, has temporarily suspended processing the energy service request from a potential 500 MW data center developer amid community concerns and to seek broader alignment with governmental agencies and stakeholders. The company emphasizes the need for a coordinated planning process, regulatory approvals, and ensuring tha…

Rhythm Pharmaceuticals to Announce Interim Six-Month Phase 2 Results Evaluating Setmelanotide in Patients with Prader-Willi Syndrome

Rhythm Pharmaceuticals to Announce Interim Six-Month Phase 2 Results Evaluating Setmelanotide in Patients with Prader-Willi Syndrome

Rhythm Pharmaceuticals announced a live webcast and conference call to discuss interim six-month results from its Phase 2 clinical trial of setmelanotide in patients with Prader-Willi syndrome. Setmelanotide is an FDA-approved MC4R agonist currently used to treat various rare genetic and hypothalamic obesity disorders. The company is expanding clin…

Monolithic Power Systems Announces Second Quarter 2026 Dividend

Monolithic Power Systems Announces Second Quarter 2026 Dividend

Monolithic Power Systems, a Nasdaq-listed semiconductor company, announced a quarterly dividend of $2.00 per share for Q2 2026, payable on July 15, 2026. This dividend declaration underscores the company's robust financial health and commitment to returning value to shareholders. MPS specializes in high-performance semiconductor power electronics w…

Village Super Market, Inc. Declares Quarterly Dividend

Village Super Market, Inc. Declares Quarterly Dividend

Village Super Market, Inc. declared quarterly dividends of $0.25 for Class A shares and $0.1625 for Class B shares, payable on July 23, 2026, to shareholders of record as of July 2, 2026. The company operates 34 supermarkets under ShopRite and Fairway banners and Gourmet Garage specialty markets across several states.

Cosmos Health Receives New Contract Manufacturing Orders Totaling 253,657 Units Across a Range of Medicines

Cosmos Health Receives New Contract Manufacturing Orders Totaling 253,657 Units Across a Range of Medicines

Cosmos Health Inc., a diversified global healthcare company listed on NASDAQ under ticker COSM, announced that its subsidiary Cana Laboratories has received new contract manufacturing orders totaling 253,657 units across multiple pharmaceutical products. These orders come from partners Nassington and Verisfield, highlighting demand for Cana's manuf…

Park Ha Biological Technology Co., Ltd. Announces Pricing of $2.0 Million Registered Direct Offering

Park Ha Biological Technology Co., Ltd. Announces Pricing of $2.0 Million Registered Direct Offering

Park Ha Biological Technology Co., Ltd., traded on NASDAQ under the ticker BYAH, has priced a registered direct offering of up to 1,133,332 Class A ordinary shares and pre-funded warrants to raise approximately $2.0 million. The offering is expected to close around June 15, 2026, with proceeds intended to support general corporate and working capit…

SL BIO Ltd. and Horizon Space Acquisition II Announce Closing of Business Combination and Listing on the Nasdaq Global Market

SL BIO Ltd. and Horizon Space Acquisition II Announce Closing of Business Combination and Listing on the Nasdaq Global Market

SL Science Holding Limited, the post-merger entity of Taiwan-based SL BIO Ltd. and Horizon Space Acquisition II, has commenced trading on Nasdaq under the ticker SLBT. The business combination valued SL Bio around $5.568 billion, supported by a $7.8 million PIPE financing, advancing SL Bio’s proprietary Gamma delta T cell therapies for solid tumors…

Precipio is requesting Shareholders/Brokers vote today to avoid costly adjournment and rescheduling of Annual Shareholders Meeting

Precipio is requesting Shareholders/Brokers vote today to avoid costly adjournment and rescheduling of Annual Shareholders Meeting

Precipio, Inc., a specialty cancer diagnostics company listed on NASDAQ under the ticker PRPO, is requesting that shareholders instruct their brokers to vote immediately to reach the quorum required for its annual shareholders meeting scheduled for June 15, 2026. Currently, only about 42% of shares are voted; 50% is needed to avoid costly adjournme…